{
    "clinical_study": {
        "@rank": "102575", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo adjunct to open-label treatment with a commercially available approved treatment for PTSD"
            }, 
            {
                "arm_group_label": "Brexpiprazole", 
                "arm_group_type": "Experimental", 
                "description": "Brexpiprazole adjunct to open-label treatment with a commercially available approved treatment for PTSD"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the efficacy of brexpiprazole as adjunctive treatment to paroxetine or\n      sertraline on PTSD symptoms."
        }, 
        "brief_title": "Brexpiprazole as an Additional Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)", 
        "condition": [
            "Post-traumatic Stress Disorder", 
            "PTSD"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Stress Disorders, Post-Traumatic", 
                "Stress Disorders, Traumatic", 
                "Stress, Psychological"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The patient has PTSD, diagnosed according to DSM-IV-TR\u2122 and confirmed by the Mini\n             International Neuropsychiatric Interview (MINI).\n\n          -  The patient has a pre-defined Clinician-Administered PTSD Scale Part 2 (CAPS-2) total\n             score at Screening and Baseline Visits.\n\n          -  The reported duration of the PTSD is at least 3 months.\n\n        Exclusion Criteria:\n\n          -  The index traumatic event that led to development of PTSD took place more than 15\n             years before screening.\n\n          -  The patient has a severe personality disorder that in the investigator's opinion may\n             interfere with the conduct of the study.\n\n          -  The patient is at significant suicidal risk.\n\n        Other inclusion and exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "592", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01987960", 
            "org_study_id": "14865A", 
            "secondary_id": "2012-004982-41"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "Once daily, tablets, orally", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Brexpiprazole", 
                "description": "Up to 3 mg/day, once daily dose, tablets, orally", 
                "intervention_name": "Brexpiprazole", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Paroxetine", 
                "Sertraline"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 13, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dayton", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "45417"
                }, 
                "name": "US005"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose Study of Brexpiprazole as Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)", 
        "overall_contact": {
            "email": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S"
        }, 
        "overall_official": {
            "affiliation": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Clinician-Administered PTSD Scale Part 2 (CAPS-2)", 
            "measure": "Change from randomisation in PTSD symptoms using CAPS-2 total score", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Week 28"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01987960"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Clinical Global Impression - Severity of Illness (CGI-S)", 
                "measure": "Change from randomisation in global clinical impression using CGI-S score", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 28"
            }, 
            {
                "description": "Sheehan Disability Scale (SDS)", 
                "measure": "Change from randomisation in functioning using SDS score", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 28"
            }, 
            {
                "description": "Number of adverse events", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 28 weeks and a 30-day telephone contact or clinic visit"
            }, 
            {
                "description": "Number of withdrawals", 
                "measure": "Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 28 weeks"
            }
        ], 
        "source": "H. Lundbeck A/S", 
        "sponsors": {
            "collaborator": {
                "agency": "Otsuka Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "H. Lundbeck A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}